Durvalumab consolidates treatment breakthroughs: Significantly prolongs the survival of confined small cell lung cancer 26/09/2025
The U.S. Food and Drug Administration (FDA) approved the IDH1/2 inhibitor Vorasidenib for patients with specific astrocytoma or oligodendrocytoma 17/09/2025
Another new targeted drug for cholangiocarcinoma! IDH1 inhibitor Ivosidenib significantly reduces the risk of death. 08/06/2022 Bile duct cancer IDH1
Tibsovo submits supplemental New Drug Application to double survival rate for IDH1-mutant leukemia. 06/06/2022 白血病 IDH1
